4d
Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10%
Q2 2026 earnings call recap: raised HIV/PrEP outlook, Yeztugo momentum, Veklury reset, and deal-driven EPS hit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results